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Abstract
Enteric hyperoxaluria can lead to renal failure. There have only been a few reports of renal
transplantation as treatment of endstage renal disease secondary to enteric hyperoxaluria and
results have been mixed. This report describes a patient with Crohn's disease who developed
chronic renal failure from enteric hyperoxaluria. He subsequently had a successful renal transplant
without any post-operative oxalate related complications and has satisfactory renal function almost
three years later. Aggressive pre-transplant hemodialysis was not done. The literature associated
with renal transplantation for enteric hyperoxaluria is reviewed.
Background
Enteric hyperoxaluria may occur in patients with intesti-
nal malabsorption from a variety of causes. Complica-
tions include oxalate stone disease, acute renal failure,
and oxalate induced interstitial nephritis with the devel-
opment of chronic renal insufficiency. There have been
rare reports of renal transplantation for the resulting end
stage renal disease and these reports have often been com-
plicated by oxalate deposition and renal insufficiency or
graft loss [1-5]. This report is of a patient with longstand-
ing Crohn's disease, short bowel syndrome from surgery
with resultant hyperoxaluria and renal failure secondary
to recurrent stone disease. He underwent successful
deceased donor renal transplantation without any post-
op oxalate related complications and with satisfactory
renal function almost three years post transplant.
Case Presentation
The patient is a 60 year old white male who had Crohn's
disease diagnosed in the 1960's. He had small bowel
resections in 1965 and 1969. He developed recurrent
stone disease in the early 1980's. In 1999 24 hour urine
studies showed an elevated oxalate excretion of 1.29
mmol (normal <0.50 mmol) and low magnesium, citrate,
and calcium excretion. His serum creatinine was 2.0 mg%
in 1995 and 2.5 mg% in Nov. 2001. In June, 2002 he pre-
sented with acute renal failure secondary to obstructive
stone disease with a serum creatinine of 12.7 mg%. With
correction of the obstruction his renal function only mod-
estly improved and he was placed on hemodialysis on 7/
29/02. His dialysis course was complicated by multiple
blood access problems and several episodes of life-threat-
ening sepsis. As a result he underwent deceased donor
renal transplant on 3/9/04. Induction therapy consisted
of basiliximab, mycophenolate mofetil, and steroids and
then maintenance therapy with tacrolimus, sirolimus, and
steroids was instituted. The patient did not undergo inten-
sive hemodialysis either prior to or after transplantation.
He did have an acute rejection episode. The biopsy
showed Banff 1b acute rejection, but no evidence of
oxalate deposition. 24 hour urinary oxalate excretion was
elevated at 113.3 mg (normal = 3.6–38 mg/24 hr). His
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rejection episode was treated with antithymocyte globulin
(rabbit) with an excellent response. He was discharged on
calcium with meals, Urocit-K, a low oxalate diet, and pyri-
doxine. His post-hospital course has been uneventful and
his serum creatinine is 1.5 mg% almost three years later.
Discussion
Under normal circumstances ingested calcium binds with
oxalate in the intestines to form an insoluble complex.
With extensive intestinal bypass or short gut situations
malabsorption and steatorrhea cause intraluminal cal-
cium to bind preferentially with bile salts. Thus, more
oxalate is absorbed. In addition, colonic absorption of
oxalate increases due to mucosal alterations brought
about by the entry of malabsorbed fatty acids and bile
salts into the colon. Other possible contributing factors
include metabolic acidosis, a concentrated urine from
chronic diarrhea, and reduced urinary concentration of
magnesium and citrate [6].
Oxalate deposition can lead to an interstitial inflamma-
tory response and interstitial fibrosis. This appears to be
caused by a variety of toxic responses in renal epithelial
cells to oxalate exposure including altered membrane sur-
face properties, changes in gene expression, disruption of
mitochondrial function, formation of reactive oxygen spe-
cies, activation of phospholipase A2, upregulation of
cyclooxygenase-2, and decreased cell viability [7].
Increased synthesis of osteopontin, bikunin, heparan sul-
fate, monocyte chemoattractant protein 1, and prostag-
landin E2 which are known to participate in
inflammatory processes and in extracellular matrix pro-
duction has also been noted [8].
Treatment of hyperoxaluria could include oral calcium
supplements given with meals to bind intestinal oxalate,
cholestyramine to bind bile salts and fatty acids, increased
oral fluids, citrate administration, a low oxalate, high cal-
cium, low fat diet, use of an organic marine hydrocolloid
that helps adsorb oxalate within the gut lumen, colonic
degradation of endogenous oxalate by orally adminis-
tered Oxalobacter formigenes, and treatment of the pri-
mary cause such as converting a jejunal-ileal bypass to a
roux-en-y bypass.
The plasma oxalate level increases starting at a glomerular
filtration rate of about 30 ml/min and oxalate retention
increases rapidly when the glomerular filtration rate
decreases below about 20 ml/min [7]. In otherwise nor-
mal dialysis patients serum oxalate levels remain elevated
even though dialysis removes significant mounts of
oxalate [8]. However, significant organ dysfunction does
not generally occur in the dialysis population [9]. In addi-
tion, substantial oxalate deposition post transplant gener-
ally does not occur [10].
There have only been a few reports of renal transplanta-
tion in patients with endstage renal disease secondary to
enteric hyperoxaluria. Results have been mixed. Roberts et
al [1] reported a patient who had stable renal function
(serum creatinine of 120 mmol/L) 10 months after trans-
plant inspite of having to be treated for an acute rejection
episode on day 21. A renal biopsy at that time did not
show any oxalate deposition. No further followup is
given. Cuvelier et al [2] reported a patient who had two
successive renal transplants 7 months apart. Both grafts
showed widespread oxalate deposition on early biopsies
and neither graft initially functioned. The second graft's
function improved sufficiently 11 months after transplant
to allow discontinuation of dialysis. Approximately 4
years later serum creatinine was 3.0 mg%. Kistler et al [3]
reported a patient who had a creatinine clearance of 60–
70 ml/min seven years after transplant inspite of the dem-
onstration of oxalate crystal deposition on day 9 after
transplant. This patient underwent intensive hemodialysis
after the transplant. Bernhardt et al [4] report a patient
who received daily hemodiafiltration (3 hours) for two
weeks after transplant. Biopsy on day 11 showed border-
line rejection as well as sporadic deposition of oxalate
crystals. Unfortunately, serum creatinine one and a half
years later was approximately 5 mg%. Lefaucheur [5]
mention a patient with mucoviscidosis who developed
acute oxalate-induced renal failure four months after a
nonrenal organ transplant. He had a renal transplant 3
years later with a post-transplant serum creatinine of 1
mg/dL, but no other details are given.
The results of renal transplantation alone for the treat-
ment of renal failure secondary to primary hyperoxaluria
type I, a disease with substantial overproduction of
oxalate, are generally not adequate. The addition of liver
transplantation, which corrects the enzyme deficiency,
produces better results [13]. This suggests that the present
patient will require continued monitoring and treatment
of his enteric hyperoxaluria.
Conclusion
Renal transplantation for chronic renal failure resulting
from enteric hyperoxaluria is a reasonable treatment
option. Aggressive pre-transplant dialysis may not be nec-
essary.
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